Investment Highlights
Bod Science (ASX:BOD) is a cannabis focused drug development and product innovation company.
ASX:BOD
The acquisition of Aqua Phase has been a strategic and methodological process, with a number of key milestones along the way.
We are increasingly confident in the commercial potential of this unique delivery format in numerous global markets.
Aqua Phase promises to enable poor solubility medications to become cheaper and safer as a result of lower side effects and less use of the active ingredient required due to the medications increased solubility. The solubility data we have already demonstrated from the UV analysis enables us to move a number of commercial opportunities in cannabis and non-cannabis medications forward with increasing confidence.
Jo Patterson CEO
Aqua Phase – The Technology
Bod has acquired a world-first invention known as ‘Aqua Phase’ and related assets (“Aqua Phase”), from two scientists located in the United Kingdom
- Product and process technology with potential to increase bioavailability of lipophilic Cannabis compounds in humans up to 4 times, optimising oral delivery, and solving intrinsic problem of bioavailability
- Increasing bioavailability (active biological effect) can lead to faster onset, better efficacy and lower dosing, resulting in fewer side effects
- Patent protected product. Uses a common compound combined with CBD and/or other Cannabis and lipophilic compounds under specific mechanical and heating processes to deliver a stable, highly bioavailable compound
- Finished product in powder form is expected to be presented in multiple formats; bulk powders, capsules, tablets, fast dissolves and concentrates with application in fast-growing supplement and pharmaceutical sectors
- Invention uniqueness the primary IP surrounding the combination; the exact proportions of active and modified starch are precisely defined
- Specific temperatures and agitation process are set, delivering a powder that is flavourless, colourless and stable
Competitive Landscape
Ultraviolet (UV) Analysis of Solubility
Aqua Phase CBD solubility ranges 1.6 millimolar (mM) to 2.7mM under various conditions
VS
Standard CBD solubility is 0.2 micromolar (μM)
| Aqua Phase | Emulsifiers | Nano Technology | Phospholipids | |
| Water Soluble vs Dispersible | Water Soluble | Water Dispersible | Water Dispersible | Water Dispersible |
| Delivery Platform | Modified Search | Phospholipid | Phospholipid | Phospholipid |
| Format | Powder | Liquid | Liquid | Liquid |
| Bioavailability |
Aqua Phase CBD Combination
CBD
The exact proportions of active (CBD) and substrate (starch based molecule) are defined
Heat and agitation
Starch Based Molecule
Specific temperatures and the agitation process are set Invention offers an API that is flavourless, colourless and stable
Bioavailable
CBD
Aqua Phase
Results Summary
Pharmacokinetic (PK) analysis showed that Aqua Phase CBD statistically outperformed CBD oil
Total CBD availability (as measured by area under the curve, AUC) showed that Aqua Phase CBD was statistically significantly greater than CBD oil by 311% (4.1x)
The maximum concentration (Cmax) was also statistically significantly higher at 277% (3.8x) more than CBD oil
Aqua Phase
Pharmacokinetic Studies
Study 1
Aqua Phase PK Study
Bioavailability in Capillary Blood
Study 2
Phase 1 Aqua Phase PK Study
Bioavailability in Venous Blood
Phase IIB Insomnia Clinical Trial for Schedule 3 CBD Medication
Bod anticipates to deliver the first over-the-counter (OTC) Cannabis product to be submitted to the TGA for an ARTG registration.
Successful receipt of ARTG registration will elevate Bod to be one of only two companies globally to have a registration of a Cannabis product (Jazz Pharma).
- In conjunction with The Woolcock Institute, Bod is undertaking a clinical trial testing the efficacy of Bod’s CBD ECS Bioabsorb Softgel (utilising Bod’s Aqua Phase Technology) vs Epidiolex CBD Oil Solution when used to treat insomnia, to follow with submission for a Schedule 3 CBD medication
- ARTG registration is granted under the TGA regime. It requires the submission of a dossier, including results of a gold standard clinical trial (double blinded placebo) and efficacy results relating to the primary end point
- An approval will have a significantly beneficial impact on access for customers / patients with insomnia. The product will no longer require a prescription and will be available through pharmacy (OTC)
- It will set the benchmark for future studies and submissions to the TGA and registrations of Cannabis products
- It is anticipated achieving a successful trial, along with being the first registered cannabis CBD product in Australia will have a significant and positive overall impact on the Australian Cannabis industry
Phase IIB Insomnia Clinical Trial
for Schedule 3 CBD Medication
